THER-09. IMPACT OF KRAS MUTATION STATUS ON THE EFFICACY OF IMMUNOTHERAPY IN LUNG CANCER BRAIN METASTASES

BACKGROUND: Immunotherapy is increasingly used in patients with non-small cell lung cancer brain metastases (NSCLCBM). KRAS mutations are associated with worse prognosis and there is no FDA approved targeted therapy. KRAS mutations are associated with increased expression of PD-L1. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauko, Adam, Ali, Assad, Sagar, Soumya, Barnett, Addison, Li, Hong, Chao, Samuel, Pennell, Nathan, Stevens, Glen, Peereboom, David, Yu, Jennifer, Murphy, Erin, Angelov, Lilyana, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213262/
http://dx.doi.org/10.1093/noajnl/vdz014.052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213262/
http://dx.doi.org/10.1093/noajnl/vdz014.052

Ejemplares similares